Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda
Annals of Tropical Medicine and Parasitology, Volume 102, No. 1, Year 2008
Notification
URL copied to clipboard!
Description
Between September 2003 and April 2004, the supply of antimonial drugs to Amudat Hospital, in north-eastern Uganda, was interrupted and all cases of visceral leishmaniasis presenting at the hospital could only be treated with amphotericin B deoxycholate (AmB). This allowed the safety and effectiveness of the AmB to be evaluated, in comparison with an historical cohort of patients treated, at the same hospital, with meglumine antimoniate (SbV). Demographic and clinical data were collected before and after treatment. Adverse effects were recorded passively in all the subjects, and actively, using a standardized questionnaire, in a sub-group of the patients given AmB. The inhospital case-fatality 'rates' were 4.8% [95% confidence interval (CI)=2.4%-8.8%] among the 210 patients treated with AmB and 3.7% (CI=1.4%-7.9%) among the 161 patients treated with SbV (P>0.20). Adverse effects requiring treatment interruption were rare in both cohorts. Treatment failures (i.e. non-responses or relapses) were observed in 2.9% (CI=1.2%-6.4%) of the patients treated with AmB and 1.2% (CI=0.1%-4.4%) of the patients treated with SbV (P>0.20). For the treatment of visceral leishmaniasis in Uganda, AmB therefore had a similar effectiveness and safety profile to that of meglumine antimoniate. © 2008 The Liverpool School of Tropical Medicine.
Authors & Co-Authors
Mueller, Yolanda Kathrin
Switzerland, Geneva
Medecins Sans Frontieres
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Nguimfack, Alexandre
Switzerland, Geneva
Medecins Sans Frontieres
Cavailler, Philippe
France, Paris
Epicentre
Couffignal, Sophie
Switzerland, Geneva
Medecins Sans Frontieres
Rwakimari, John Bosco
Uganda, Kampala
Uganda Ministry of Health
Loutan, Louis
Switzerland, Geneva
Hôpitaux Universitaires de Genève
Chappuis, François P.
Switzerland, Geneva
Medecins Sans Frontieres
Switzerland, Geneva
Hôpitaux Universitaires de Genève
Statistics
Citations: 31
Authors: 7
Affiliations: 5
Identifiers
Doi:
10.1179/136485908X252142
ISSN:
00034983
Research Areas
Health System And Policy
Study Design
Cohort Study
Study Locations
Uganda